Capricor Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Linda Marbán
- Full Time Employees
- 231
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 10865 Road to the Cure San Diego CA United States 92121
- IPO Date
- Jun 4, 2002
- CIK
- 0001133869
- Website
- capricor.com
- Similar Companies
- Business
- Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company that develops transformative cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy and other rare diseases with high unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company focuses on allogeneic cardiosphere-derived cells and engineered exosomes, targeting primary markets in the United States, Japan, and Europe through strategic partnerships. Its lead product candidate, deramiocel (also known as CAP-1002), comprises cardiosphere-derived cells that provide immunomodulatory, anti-fibrotic, anti-inflammatory, and regenerative effects via exosome-mediated mechanisms, including microRNAs that alter gene expression to reduce inflammation and promote tissue repair in dystrophinopathies; deramiocel has completed the Phase 3 HOPE-3 trial, demonstrating statistically significant improvements in skeletal and cardiac function, building on durable benefits observed in the HOPE-2 trial and its over 48-month open-label extension. The company advances a proprietary StealthX exosome platform for precision-engineered therapeutics, including targeted delivery of RNA, proteins, small molecules, and vaccines; this encompasses preclinical and early-stage programs such as an NIAID-funded Phase 1 exosome-based vaccine candidate for infectious diseases with topline data expected in early 2026, alongside CAP-2003 for DMD and broader applications in inflammatory and regenerative medicine. Capricor maintains license agreements with institutions including Johns Hopkins University, University of Rome, Cedars-Sinai Medical Center, and Life Technologies to support its cell and exosome technologies. In recent developments, Capricor announced positive topline results from the pivotal Phase 3 HOPE-3 study of deramiocel in December 2025, prompting plans for a Biologics License Application resubmission to the FDA by year-end incorporating this data to address prior manufacturing observations from a Complete Response Letter; the company expanded its partnership with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. in 2024 to include exclusive commercialization and distribution rights for deramiocel in Europe alongside the existing U.S. and Japan agreements, which provide upfront payments, development and sales milestones up to approximately $89 million, and double-digit royalties. Capricor reports a cash position of approximately $99 million as of Q3 2025, sufficient to fund operations into late 2026 amid commercial launch preparations for potential 2026 market introduction and ongoing exosome platform advancement.
Company News
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
Inflation Breather Could Help Stocks Finish Q3 Strong
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
CAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
CAPR FINAL DEADLINE: ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to Their Right to Seek Lead Plaintiff Status Before September 29, 2026
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline